IMProving Executive Function Study

Following a medically induced menopause, many women report difficulty in remembering things,
focusing and concentrating. The purpose of this study is to examine the effects of a
stimulant medication called Vyvanse® (lisdexamfetamine; LDX) on executive functioning, such
as attention, processing, organization, and memory, in women who are experiencing executive
functioning difficulties after having undergone a risk-reducing bilateral
salpingo-oophorectomy (RRSO). This study involves magnetic resonance imaging (MRI) to see how
LDX affects brain chemistry while undergoing two 6-week trials of the study drug and placebo
capsules.

Individuals wishing to participate in this study are medically healthy women between the ages
of 35-58 years old who have undergone a risk-reducing bilateral salpingo-oophorectomy (RRSO)
within the previous 15 years. Participants must have been premenopausal before undergoing
RRSO (meaning they were having regular periods). They also must not have undergone radiation
or chemotherapy in the past year.

Furthermore, participants must not suffer from a mental illness, including Attention Deficit
Hyperactivity Disorder (ADHD), and must not have a recent history of drug abuse.
Additionally, participants must not suffer from a fear of small, enclosed spaces
(claustrophobia), and not have any implanted medical devices such as a pacemaker, orthodontic
braces, or shrapnel. They must not have a history of seizures, uncontrolled hypertension or
known renal impairment.

Inclusion Criteria:

- Female;

- Age 35-58;

- Have undergone risk-reducing bilateral salpingo-oophorectomy (RRSO) within the
previous 15 years AND were premenopausal at the time of RRSO;

- Score of ≥ 20 on the Brown Attention Deficit Disorder Scale (BADDS);

- Onset of executive function difficulties occurred post RRSO;

- Clean urine drug screen (nicotine and marijuana are permissible);

- Are fluent in written and spoken English;

- Are able to give written informed consent (obtained at screening visit);

- Have a high school diploma or equivalent degree (i.e., GED), as per subject report;

- If using aromatase inhibitors or tamoxifen: Must have been on a stable dose for at
least 6 months;

- If completing visits remotely: Must have access to a telecommunications application
(i.e., Skype), email, scanner/fax machine, and a private area that enables the
protection of participant confidentiality.

Exclusion criteria:

- Current, untreated psychiatric disorder;

- Substance use disorder within the previous 3 years;

- Lifetime history of ADHD or psychotic disorder including bipolar disorder,
schizoaffective disorder, and schizophrenia;

- Lifetime history of stimulant abuse or dependence;

- Regular use of psychotropic medications except selective serotonin reuptake inhibitors
(SSRI), serotonin noradrenergic reuptake inhibitors (SNRI), bupropion, zolpidem,
gabapentin, or buspirone;

- Chemotherapy within the past year;

- Previous history of sensitivity or adverse reaction to lisdexamfetamine (LDX);

- History of seizures or unstable medical condition;

- Known heart disease or clinically significant abnormal electrocardiogram during
screening as determined by the study MD;

- Uncontrolled hypertension;

- Presence of a metallic implant contraindicative to scanning at the 7T level;

- Claustrophobia.

- Consistent systolic blood pressure of >145mm Hg or diastolic blood pressure >90 mm Hg
after three readings at time of screening;

- Known renal impairment and End Stage Renal Disease (ESRD).